Abstract:The US Preventive Services Task Force (USPSTF) last released recommendations on breast cancer screening in 2016, when they recommended that most women be screened every 2 years starting at age 50 years. In their 2024 recommendations, 1 -3 the USPSTF now recommends initiating screening mammography for all women at age 40 years and screening every 2 years until age 74 years (B recommendation). Similar to the 2016 recommendations, in their updated recommendations, 1 -3 the USPSTF concludes that evidence is insufficient to assess the balance of benefits and harms of screening mammography in women aged 75 years and older (I statement) and that evidence is insufficient to assess the role of supplemental screening for women with dense breasts (I statement). Beyond the change in the recommended age to initiate screening, the new recommendations differ from prior recommendations in 2 critical and related ways: a deliberate focus on health equity and greater reliance on evidence from studies other than randomized clinical trials (RCTs). The 2024 USPSTF recommendations 1 -3 adopt a deliberate focus on health equity, aligning with the USPSTF's effort to incorporate heath equity, race, and antiracism into their recommendations. 4 The 2024 recommendations 1 -3 explicitly strive to address the persistent inequity in breast cancer mortality experienced by Black women in the US, who—despite having lower lifetime breast cancer incidence—are 40% more likely to die of the disease. 5 The reasons for this disparity are thought to be multifactorial and complex but rooted in systemic racism. Black women are more likely than White women to have mammograms of lower quality (despite comparable screening rates), experience longer delays to definitive diagnosis and treatment, and receive less guideline-concordant care. 6 Black women have higher breast cancer incidence in their 30s and 40s than White women and are more likely to have aggressive tumor subtypes, such as triple-negative cancers, perhaps related to the effects of environmental exposures and systemic racism. 5 Whether and how inequitable breast cancer outcomes should inform breast cancer screening practices is uncertain. Notably, RCTs of mammography screening, and even large observational studies, have included few women of color and thus do not shed light on racial and ethnic differences in the benefits and harms of screening. To inform its current recommendations, 1 -3 the USPSTF commissioned a new modeling study assessing the benefits and harms of mammography screening in the average-risk population of US women overall and for Black women specifically. Model inputs included real-world data on treatment, including inferior treatment received by Black women, and higher breast cancer mortality rates among Black women. Across all women, the models estimated that screening every 2 years between ages 50 and 74 years would avert an estimated 6.7 breast cancer deaths per 1000 people screened, while biennial screening starting at age 40 years would avert an additional 1.3 breast cancer deaths. Among Black women, screening every 2 years between ages 50 and 74 would avert an estimated 9.2 breast cancer deaths per 1000 persons screened, while biennial screening starting at age 40 years would avert an additional 1.8 breast cancer deaths. However, screening every 2 years starting at age 40 years also would lead to more false positive tests (1376 false positives per 1000 screened in the general population, and 1253 false positives per 1000 screened in Black women, over a lifetime) and overdiagnosed cancers (ie, cancers that would never become clinically evident in a woman's lifetime in the absence of screening; 14 cancers per 1000 women screened in the general population, and 18 cancers per 1000 women screened among Black women). 1 ,3 Overall, the models suggest that compared with the general population, Black women would derive more benefit from screening, including from starting screening in their 40s, although the additional benefit of screening starting at age 40 years vs age 50 years was small in both groups. Modeling studies can shed light on questions for which RCT data are not available, and the use of modelling to examine the effects of systemic racism and inform strategies to mitigate these effects is intriguing. 7 However, modeling studies also have important limitations, including their reliance on inputs and assumptions that may or may not be transparent or universally agreed on. For example, the USPSTF model identified a breast cancer mortality reduction from mammography of 30% for screening women aged 40 to 74 years, which is substantially higher than reductions from mammography observed in RCTs (8% for women in their 40s and 14% for women in their 50s).<s -Abstract Truncated-

Skin cancer screening recommendations by U.S. cancer centers: Inconsistency with national guidelines

Public cervical cancer screening recommendations from US cancer centers: Assessing adherence to national guidelines

Association Between Health Maintenance Practices and Skin Cancer Risk As a Possible Source of Detection Bias

Screening and Prevention Measures for Melanoma: Is There a Survival Advantage?

Recent Changes in Prostate Cancer Screening Practices and Epidemiology

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.

303 Health Maintenance Practices Associated with Incident Skin Cancer in US Women and Men

New Recommendations for Breast Cancer Screening—In Pursuit of Health Equity

Cancer overdiagnosis: a challenge in the era of screening

How Do Cancer Screening Guidelines Trade off Benefits Versus Harms and Burdens of Screening? A Systematic Survey

Patients poorly recognize lesions of concern that are malignant melanomas: is self-screening the correct advice?

National Trends in PSA Cancer Screening With Parallel Investigation of Colorectal Cancer Screening: An Analysis of the CDC Behavioral Risk Factor Surveillance System From 2012 to 2022

Abstract A135: Social disparities in breast cancer screening: Up-to-date screening versus overscreening

Assessment of US Preventive Services Task Force Guideline-Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019

Why do older adults stop cancer screening? Findings from the Medicare Current Beneficiary Survey

A synthesis of evidence for cancer-specific screening interventions: A Preventive Medicine Golden Jubilee Review

The 2021 US Preventive Services Task Force lung cancer screening eligibility criteria disproportionately exclude younger Black patients with lung cancer

Screening for Testicular Cancer: An Evidence Review for the U.S. Preventive Services Task Force

Colorectal cancer screening test exposure patterns in US adults 45 to 49 years of age, 2019-2021

Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems

Screening for cancer: concepts and controversies